ERBB2 and breast cancer: The PyMT mammary tumours progress with some morphological similarities to human cancer pathology, along with a similar pattern of expression of breast cancer biomarkers (such as loss of estrogen and progesterone receptors, and overexpression of cyclin D1 and erbB2/neu), making it a robust model to study tumour progression and microenvironment [14].